CA3073919A1 - Cyclic di-nucleotides as stimulator of interferon genes modulators - Google Patents

Cyclic di-nucleotides as stimulator of interferon genes modulators Download PDF

Info

Publication number
CA3073919A1
CA3073919A1 CA3073919A CA3073919A CA3073919A1 CA 3073919 A1 CA3073919 A1 CA 3073919A1 CA 3073919 A CA3073919 A CA 3073919A CA 3073919 A CA3073919 A CA 3073919A CA 3073919 A1 CA3073919 A1 CA 3073919A1
Authority
CA
Canada
Prior art keywords
alkyl
compound
independently
cycloalkyl
img
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA3073919A
Other languages
English (en)
French (fr)
Inventor
Yuntao Song
Anrong LI
Xiaoqi Chen
Original Assignee
Beijing Xuanyi Pharmasciences Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beijing Xuanyi Pharmasciences Co Ltd filed Critical Beijing Xuanyi Pharmasciences Co Ltd
Publication of CA3073919A1 publication Critical patent/CA3073919A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/04Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D519/00Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7084Compounds having two nucleosides or nucleotides, e.g. nicotinamide-adenine dinucleotide, flavine-adenine dinucleotide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16Purine radicals
    • C07H19/20Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • C07H19/213Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids containing cyclic phosphate
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/02Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H23/00Compounds containing boron, silicon or a metal, e.g. chelates or vitamin B12

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pulmonology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Steroid Compounds (AREA)
CA3073919A 2017-08-30 2018-08-30 Cyclic di-nucleotides as stimulator of interferon genes modulators Abandoned CA3073919A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762552148P 2017-08-30 2017-08-30
US62/552,148 2017-08-30
US201862660565P 2018-04-20 2018-04-20
US62/660,565 2018-04-20
PCT/IB2018/056658 WO2019043634A2 (en) 2017-08-30 2018-08-30 CYCLIC DI-NUCLEOTIDES AS STIMULATORS OF INTERFERON GENE MODULATORS

Publications (1)

Publication Number Publication Date
CA3073919A1 true CA3073919A1 (en) 2019-03-07

Family

ID=65527221

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3073919A Abandoned CA3073919A1 (en) 2017-08-30 2018-08-30 Cyclic di-nucleotides as stimulator of interferon genes modulators

Country Status (14)

Country Link
US (1) US11773132B2 (enExample)
EP (1) EP3692048A4 (enExample)
JP (1) JP7311514B2 (enExample)
KR (1) KR102782200B1 (enExample)
CN (1) CN111263767B (enExample)
AU (1) AU2018323053A1 (enExample)
BR (1) BR112020004047A2 (enExample)
CA (1) CA3073919A1 (enExample)
IL (1) IL272928A (enExample)
MX (1) MX2020002303A (enExample)
RU (1) RU2020112502A (enExample)
SG (1) SG11202001847WA (enExample)
TW (1) TWI808092B (enExample)
WO (1) WO2019043634A2 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114751950B (zh) 2016-03-18 2025-04-18 免疫传感器公司 环二核苷酸化合物及使用方法
PT3512861T (pt) 2016-12-01 2021-04-29 Takeda Pharmaceuticals Co Dinucleotídeos cíclicos
JP7591348B2 (ja) 2017-02-21 2024-11-28 ボード オブ レジェンツ,ザ ユニバーシティ オブ テキサス システム インターフェロン遺伝子刺激因子依存性シグナル伝達のアゴニストとしての環状ジヌクレオチド
KR102782200B1 (ko) 2017-08-30 2025-03-17 에이제이 사이언시즈 (이씽) 코., 엘티디 인터페론 유전자 조절인자의 자극제로서의 환식 다이-뉴클레오타이드
MX2020004858A (es) 2017-11-10 2020-10-01 Takeda Pharmaceuticals Co Compuestos moduladores de sting y metodos de elaboracion y uso.
US11945834B2 (en) * 2018-03-08 2024-04-02 Bristol-Myers Squibb Company Cyclic dinucleotides as anticancer agents
MX2020012964A (es) 2018-06-01 2021-02-16 Eisai R&D Man Co Ltd Metodos para el tratamiento de cancer de vejiga.
JP7492523B2 (ja) * 2018-10-12 2024-05-29 シャンハイ ジェミンケア ファーマシューティカル カンパニー,リミティド 環状ジヌクレオチド化合物及びその使用
US12435104B2 (en) * 2019-07-25 2025-10-07 Beigene, Ltd. Cyclic dinucleotides as sting agonists
WO2021178818A2 (en) * 2020-03-06 2021-09-10 Beijing Xuanyi Pharmasciences Co., Ltd. Therapeutic agents and conjugates thereof
WO2021206158A1 (ja) 2020-04-10 2021-10-14 小野薬品工業株式会社 がん治療方法
CN111592570B (zh) * 2020-05-15 2022-04-29 清华大学 新型sting激动剂及其制备方法和应用
WO2022083584A1 (zh) * 2020-10-20 2022-04-28 泰励生物科技(上海)有限公司 多功能环二核苷酸及其用途
KR102466750B1 (ko) * 2020-10-23 2022-11-15 아주대학교산학협력단 인돌리진 유도체를 유효성분으로 포함하는 인터페론 유전자 자극제 조성물
MX2023005381A (es) 2020-11-09 2023-05-23 Takeda Pharmaceuticals Co Conjugados de anticuerpo y farmaco.

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
GB9518953D0 (en) 1995-09-15 1995-11-15 Pfizer Ltd Pharmaceutical formulations
WO2000035298A1 (en) 1996-11-27 2000-06-22 Wm. Wrigley Jr. Company Chewing gum containing medicament active agents
GB9711643D0 (en) 1997-06-05 1997-07-30 Janssen Pharmaceutica Nv Glass thermoplastic systems
CN1787837A (zh) 2002-11-15 2006-06-14 希龙公司 防止和治疗癌转移以及与癌转移相关的骨质损失的方法
WO2005005450A1 (ja) 2003-07-15 2005-01-20 Mitsui Chemicals, Inc. 環状ビスジヌクレオシドの合成方法
US8367716B2 (en) * 2003-07-28 2013-02-05 Karaolis David K R Method for attentuating virulence of microbial pathogens and for inhibiting microbial biofilm formation
JP4931798B2 (ja) 2004-03-15 2012-05-16 ケイ.アール. カラオリス,デイヴィッド 免疫、炎症または神経保護応答のための方法
EP3018144A1 (en) 2006-08-18 2016-05-11 XOMA Technology Ltd. Prlr-specific antibody and uses thereof
PT2242512T (pt) 2008-01-15 2016-07-18 Univ Leland Stanford Junior Métodos para manipular a fagocitose mediada por cd47
EP2111869A1 (en) 2008-04-23 2009-10-28 Stichting Sanquin Bloedvoorziening Compositions and methods to enhance the immune system
WO2009133560A1 (en) 2008-04-29 2009-11-05 Smart Assays Non-hydrolyzable and permeable cyclic bis-[nucleotide monophosphate] derivatives and uses thereof
AU2010220421B9 (en) 2009-03-02 2015-03-05 Aduro Biotech Holdings, Europe B.V. Antibodies against a proliferating inducing ligand (APRIL)
SG187908A1 (en) 2010-08-20 2013-03-28 Novartis Ag Antibodies for epidermal growth factor receptor 3 (her3)
EA201590396A1 (ru) 2012-12-13 2015-12-30 Адуро Биотек, Инк. Композиция, содержащая циклические пуриновые динуклеотиды с определенной стереохимией, и способ ее получения и применения
US9498532B2 (en) 2013-03-13 2016-11-22 Novartis Ag Antibody drug conjugates
ES2982836T3 (es) 2013-04-29 2024-10-17 Memorial Sloan Kettering Cancer Center Composiciones y métodos para alterar la señalización de segundos mensajeros
US9549944B2 (en) 2013-05-18 2017-01-24 Aduro Biotech, Inc. Compositions and methods for inhibiting “stimulator of interferon gene”—dependent signalling
ME03586B (me) 2013-05-18 2020-07-20 Univ California Sastavi i metode za aktiviranje signaliziranja koje je zavisno od .,stimulatora gena za interferon"
EP3060056A4 (en) 2013-10-21 2017-10-18 Drexel University Use of sting agonists to treat chronic hepatitis b virus infection
EP3071229A4 (en) 2013-11-22 2017-05-10 Brock University Use of fluorinated cyclic dinucleotides as oral vaccine adjuvants
WO2015185565A1 (en) 2014-06-04 2015-12-10 Glaxosmithkline Intellectual Property Development Limited Cyclic di-nucleotides as modulators of sting
US20170340658A1 (en) 2014-12-16 2017-11-30 Invivogen Combined use of a chemotherapeutic agent and a cyclic dinucleotide for cancer treatment
ES2764178T3 (es) 2014-12-16 2020-06-02 Kayla Therapeutics Dinucleótidos cíclicos fluorados para inducción de citocinas
GB201501462D0 (en) * 2015-01-29 2015-03-18 Glaxosmithkline Ip Dev Ltd Novel compounds
JO3746B1 (ar) * 2015-03-10 2021-01-31 Aduro Biotech Inc تركيبات وطرق لتنشيط الإشارات المعتمدة على "منبه أو تحفيز جين انترفيرون"
MX2018001814A (es) 2015-08-13 2018-05-07 Merck Sharp & Dohme Compuestos dinucleotidos ciclicos como agonistas del estimulador de genes de interferon.
UY36969A (es) 2015-10-28 2017-05-31 Novartis Ag Composiciones y métodos para activar la señalización dependiente del estimulador del gen de interferon
JP6411676B2 (ja) * 2015-12-03 2018-10-24 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドGlaxosmithkline Intellectual Property Development Limited Stingの調節因子としての環状プリンジヌクレオチド
WO2017106740A1 (en) 2015-12-16 2017-06-22 Aduro Biotech, Inc. Methods for identifying inhibitors of "stimulator of interferon gene"-dependent interferon production
HUE073018T2 (hu) 2016-01-11 2026-01-28 Innate Tumor Immunity Inc Ciklikus dinukleotidok állapotok kezelésére, amelyek STING-aktivitással kapcsolatosak, mint például rák
WO2017123657A1 (en) 2016-01-11 2017-07-20 Gary Glick Cyclic dinucleotides for treating conditions associated with sting activity such as cancer
CN114751950B (zh) 2016-03-18 2025-04-18 免疫传感器公司 环二核苷酸化合物及使用方法
WO2017186711A1 (en) * 2016-04-25 2017-11-02 Invivogen Novel complexes of immunostimulatory compounds, and uses thereof
EP3507367A4 (en) 2016-07-05 2020-03-25 Aduro BioTech, Inc. CYCLIC DINUCLEOTID COMPOUNDS WITH INCLUDED NUCLEIC ACIDS AND USES THEREOF
WO2018045204A1 (en) 2016-08-31 2018-03-08 Ifm Therapeutics, Inc Cyclic dinucleotide analogs for treating conditions associated with sting (stimulator of interferon genes) activity
US10537590B2 (en) 2016-09-30 2020-01-21 Boehringer Ingelheim International Gmbh Cyclic dinucleotide compounds
EP3523314A1 (de) * 2016-10-07 2019-08-14 Biolog Life Science Institute Forschungslabor Und Biochemica-Vertrieb GmbH Benzimidazolhaltige cyclische dinukleotide, verfahren zu deren herstellung und ihre verwendung zur aktivierung von stimulator von interferongenen (sting)-abhängigen signalwegen
JOP20170188A1 (ar) 2016-11-25 2019-01-30 Janssen Biotech Inc ثنائي النوكليوتيدات الحلقية كمنبهات ستينغ (sting)
PT3512861T (pt) 2016-12-01 2021-04-29 Takeda Pharmaceuticals Co Dinucleotídeos cíclicos
AU2017378783A1 (en) 2016-12-20 2019-07-04 Merck Sharp & Dohme Corp. Cyclic dinucleotide sting agonists for cancer treatment
WO2018119274A1 (en) * 2016-12-21 2018-06-28 Fred Hutchinson Cancer Research Center Scaffolds to treat solid tumor cells and escape variants
JP7213188B2 (ja) 2017-01-27 2023-01-26 ヤンセン バイオテツク,インコーポレーテツド Stingアゴニストとしての環状ジヌクレオチド
US11492367B2 (en) 2017-01-27 2022-11-08 Janssen Biotech, Inc. Cyclic dinucleotides as sting agonists
KR102782200B1 (ko) 2017-08-30 2025-03-17 에이제이 사이언시즈 (이씽) 코., 엘티디 인터페론 유전자 조절인자의 자극제로서의 환식 다이-뉴클레오타이드
JP7492523B2 (ja) * 2018-10-12 2024-05-29 シャンハイ ジェミンケア ファーマシューティカル カンパニー,リミティド 環状ジヌクレオチド化合物及びその使用

Also Published As

Publication number Publication date
SG11202001847WA (en) 2020-03-30
TW201919650A (zh) 2019-06-01
RU2020112502A3 (enExample) 2021-10-08
US20200331957A1 (en) 2020-10-22
MX2020002303A (es) 2020-09-10
RU2020112502A (ru) 2021-10-01
KR102782200B1 (ko) 2025-03-17
AU2018323053A1 (en) 2020-03-19
IL272928A (en) 2020-04-30
EP3692048A4 (en) 2021-10-20
BR112020004047A2 (pt) 2020-09-01
KR20200058411A (ko) 2020-05-27
TWI808092B (zh) 2023-07-11
JP2020532585A (ja) 2020-11-12
CN111263767B (zh) 2023-07-18
JP7311514B2 (ja) 2023-07-19
WO2019043634A2 (en) 2019-03-07
EP3692048A2 (en) 2020-08-12
CN111263767A (zh) 2020-06-09
WO2019043634A3 (en) 2019-04-11
US11773132B2 (en) 2023-10-03

Similar Documents

Publication Publication Date Title
US11773132B2 (en) Cyclic di-nucleotides as stimulator of interferon genes modulators
US11505571B2 (en) Compounds and compositions for treating conditions associated with sting activity
CA2975033C (en) Cdk2/4/6 inhibitors
US20230219946A1 (en) Pyrimidin-4(3h)-one heterocyclic compound, preparation method thereof, and pharmaceutical use thereof
CA3042260A1 (en) Tau-protein targeting protacs and associated methods of use
US20190345191A1 (en) Cyclic dinucleotide analogs for treating conditions associated with sting (stimulator of interferon genes) activity
CA3089527A1 (en) Autotaxin inhibitors and uses thereof
US20240066133A1 (en) Therapeutic agents and conjugates thereof
KR20120113760A (ko) 정제된 피롤로퀴놀리닐-피롤리딘-2,5-디온 조성물 및 이의 제조 방법 및 사용 방법
EP3856743A1 (en) Substituted imidazo [1, 2-a] pyridine and [1, 2, 4] triazolo [1, 5-a] pyridine compounds as ret kinase inhibitors
US20230008368A1 (en) Imidazoquinoline substituted phosphoric ester agonist, and preparation therefor and application thereof
HK40022356B (en) Cyclic di-nucleotides as stimulator of interferon genes modulators
HK1262266A1 (en) Cyclic dinucleotides for treating conditions associated with sting activity such as cancer
HK1262266B (en) Cyclic dinucleotides for treating conditions associated with sting activity such as cancer

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20240228